Employee Participation
44%
of employees engaged in the program within 90-days of access to MyOme testing
Benefits Consultants
Demand for Genomic Benefits is Growing. Value Should Too.
Genomic health benefits are quickly becoming a fixture in competitive benefits packages. But most tests being offered — including those deployed at Fortune 500 companies — sequence less than 2% of the genome, cover only one disease area, or come without clinical support1-3. MyOme sequences the whole-genome, surfaces risk across diseases and medication response, and includes board-certified genetic counseling with every result.
1. Cohn B, et al. Molecular Genetics & Genomic Medicine (2023). 2. Society for Human Resource Management. 2018 Employee Benefits: The Evolution of Benefits. SHRM (2018). 3. McDonald WS, et al. Molecular Genetics & Genomic Medicine (2020).
MyOme Benefits Package
Hereditary Disease Risk
40+ conditionsMedication Response
70+ medicationsComplex Disease Risk
Genetic Counseling
Board-certified consultations
How Genomic Risk Insights Shape Care to Reduce Healthcare Spend
Many of the most expensive healthcare claims stem from conditions that can be identified and addressed earlier. MyOme's Proactive Health tests uncover disease risk and medication response insights before conditions progress or medication-related events occur, enabling more proactive care, lower-cost interventions, and more effective prescribing. The result is a tangible strategy for helping clients stay ahead of rising healthcare and pharmacy costs.
Reduce Cancer Treatment Costs
Single-Gene Risk insights for cancers, including breast cancer, can stimulate early screening, detection, and treatment. Treating breast cancer early can reduce treatment costs by >$500K.1
>$500K
Cut Heart Disease Spend
Polygenic Risk Scores for Coronary Artery Disease (CAD) can lead to early interventions—like statin therapy—that reduce heart event risk and avoid $40K in annual treatment costs.2
~$40K
Avoid
Hospitalizations
Medication Response insights enable safe prescribing from the start. This type of screening is proven to reduce medication-related ER visits and inpatient stays by ~40%.3
~40%
Continuous Value Beyond Initial Testing
A single genomic test delivers lifelong value. By transforming whole-genome data into a continuously updated resource, MyOme helps uncover new health insights that continue to drive better care and healthcare savings year after year.
Positive net savings in first year
Significant net savings start in second year
Net savings continue to compound
*Modeled data for an active employer program.
Invest in Benefits with Proven Uptake and Impact
MyOme's employer programs drive high voluntary participation and uncover actionable health findings, helping you deliver a benefits solution with measurable engagement and meaningful results.
Disease Risk Detection
~14%
of employees tested carried at least one clinically significant, high-impact risk variant linked to a health condition
High-Risk Classification
~20%
of employees were identified as high-risk for cardiometabolic disease or cancer
*Results averaged across active employer programs.
What our partners say
Employee support and privacy
Every employee receives their results privately, with access to a certified genetic counselor to help them understand findings and plan next steps. Your organization sees only aggregate, de-identified program data — never individual results. All genomic data is encrypted, HIPAA-compliant, and never shared without the employee's explicit consent.
Ready to bring genomic benefits to your clients?
Let's find the right fit. Whether you're evaluating options for a specific employer or building genomics into your standard benefits toolkit, our team can walk you through program structure, pricing, and what implementation looks like in practice.
Prepare for your client conversations
Get more information on MyOme employer programs and how we support organizations. Explore employer resources:
